Alexion begins internal probe into sales practices
pharmafile | November 11, 2016 | News story | Medical Communications | Alexion, sales practices
Alexion Pharmaceuticals released a statement that it was to begin conducting an internal investigation into sales practices for Soliris (eculizumb) after a former employee’s allegations. The company postponed the release of its quarterly report as it conducts the investigation.
Soliris is the company’s first approved product and treats a blood disorder, paroxysmal nocturnal hemoglobinuria and the genetic disorder called hemolytic uremic syndrome.
Alexion Pharmaceuticals released a statement announcing: “The Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company’s sales practices of Soliris (eculizumab). Specifically, the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices.”
The company further released that they had not found, as yet, any instances where Soliris orders had not been placed by customers for patients or any cause for it to update or change its previously reported historical resorts.
Alexion had previously been performing well in the year to date. It had reported higher than expected profit for the third quarter and predicted that revenue from 2016 would be at the higher end of its previous guidance, in the region of $3.05 billion to £3.1 billion.
Related Content
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and …
Alexion pauses Phase III ULTOMIRIS COVID-19 trial enrolment
Alexion has paused further enrolment in the global Phase III study of ULTOMIRIS (ravulizumab-cwvz) in …
AstraZeneca to buy Alexion in $39 billion deal
British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a …